1 / 3

Beta Thalassemia and Market Insights

Beta Thalassemia (u03b2-thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.<br>

xmichael
Download Presentation

Beta Thalassemia and Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Beta Thalassemia Market Insights and Epidemiology Forecast Beta Thalassemia Beta Thalassemia (β-thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Beta Thalassemia Epidemiology Segmentation in the 6MM ● Total Prevalent Cases of Beta Thalassemia Minor ● Diagnosed Prevalence of Beta Thalassemia ● Diagnosed Beta Thalassemia Patients by Disease Type Beta Thalassemia Epidemiological Insights Observed in the 6MM (2020) ● The total prevalent Beta Thalassemia-associated minor cases was found to be approximately 12.5k in the year 2020. Beta Thalassemia Market Insight The market size of Beta Thalassemia in the 6MM was found to be almost USD 364 million in 2020. Beta Thalassemia Emerging Therapies The emerging drugs in the Beta Thalassemia market are ● Zynteglo (LentiGlobin BB305) ● Mitapivat (AG-348) ● IMR-687 ● CTX001 ● Vamifeport (VIT2763) ● Sapablursen ● Etavopivat ● DST-0509 ● SLN-124, and others Beta Thalassemia Key Players The key players working in the Beta Thalassemia market are ● Bluebird Bio

  2. ● Agios Pharmaceuticals ● Imara Inc. ● CRISPR Therapeutics ● Vertex Pharmaceuticals ● Vifor Pharma ● Ionis Pharmaceuticals ● Forma Therapeutics ● DisperSol Technologies ● SILENCE Therapeutics

More Related